Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine

Headache

Volumn 52, Issue 3, 2012, Pages 409-421

  Bagley, Christine L ^a   Rendas Baum, Regina ^b   Maglinte, Gregory A ^c   Yang, Min ^b   Varon, Sepideh F ^c   Lee, Jeff ^c   Kosinski, Mark ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b QualityMetric Incorporated   (United States)

^c ALLERGAN INC   (United States)

Author keywords

chronic migraine; health related quality of life; migraine; Migraine Specific Quality of Life Questionnaire v2.1; validation

Indexed keywords

ADULT; ANALYTICAL PARAMETERS; ANXIETY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONSTRUCT VALIDITY; CROSS-SECTIONAL STUDY; DEPRESSION; DISABILITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EMOTIONAL FUNCTION; EPISODIC MIGRAINE; FEMALE; FUNCTIONAL STATUS; HEADACHE IMPACT TEST 6; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE DISABILITY ASSESSMENT QUESTIONNAIRE; MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE V2.1; PATIENT HEALTH QUESTIONNAIRE 4; PRIORITY JOURNAL; QUESTIONNAIRE; RELIABILITY; ROLE FUNCTION PREVENTIVE; ROLE FUNCTION RESTRICTIVE; SEX DIFFERENCE; TRANSFORMED MIGRAINE; VALIDATION PROCESS; VALIDITY;

ADULT; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OBSERVATION; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84858332284     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01997.x     Document Type: Article

References (51)

1. Rasmussen BK,. Epidemiology of migraine. Biomed Pharmacother. 1995; 49: 452-455. (Pubitemid 26011406)
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M,. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-657. (Pubitemid 32777747)
3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF,. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68: 343-349. (Pubitemid 46184209)
4. Lipton RB,. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology. 2009; 72: S3-S7.
5. Olesen J, Bousser MG, Diener HC, et al,. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
6. Scher AI, Stewart WF, Liberman J, Lipton RB,. Prevalence of frequent headache in a population sample. Headache. 1998; 38: 497-506. (Pubitemid 28429337)
7. Castillo J, Munoz P, Guitera V, Pascual J,. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache. 1999; 39: 190-196. (Pubitemid 29190083)
8. Natoli JL, Manack A, Dean B, et al,. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010; 30: 599-609.
9. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD,. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2003; 43: 336-342. (Pubitemid 36417763)
10. Guitera V, Munoz P, Castillo J, Pascual J,. Quality of life in chronic daily headache-a study in a general population. Neurology. 2002; 58: 1062-1065. (Pubitemid 34298546)
11. Munakata J, Hazard E, Serrano D, et al,. Economic burden of transformed migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009; 49: 498-508.
12. Bigal ME, Serrano D, Reed M, Lipton RB,. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71: 559-566.
13. Tepper SJ, Dahlof CG, Dowson A, et al,. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache. 2004; 44: 856-864. (Pubitemid 39362309)
14. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF,. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001; 41: 638-645. (Pubitemid 32777746)
15. Holroyd KA,. Assessment and psychological management of recurrent headache disorders. J Consult Clin Psychol. 2002; 70: 656-677. (Pubitemid 34640737)
16. Tfelt-Hansen P, Block G, Dahlof C, et al,. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000; 20: 765-786. (Pubitemid 32154559)
17. Silberstein S, Tfelt-Hansen P, Dodick DW, et al,. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008; 28: 484-495. (Pubitemid 351502554)
18. Cohen JA, Beall DG, Miller DW, Beck A, Pait G, Clements BD,. Subcutaneous sumatriptan for the treatment of migraine: Humanistic, economic, and clinical consequences. Fam Med. 1996; 28: 171-177. (Pubitemid 26088107)
19. Adelman JU, Sharfman M, Johnson R, et al,. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine. Am J Manag Care. 1996; 2: 1407-1416. (Pubitemid 126466157)
20. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL,. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract. 1996; 42: 36-42. (Pubitemid 26030543)
21. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L,. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998; 38: 295-302. (Pubitemid 28194304)
22. Martin BC, Pathak DS, Sharfman MI, et al,. Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache. 2000; 40: 204-215. (Pubitemid 30169885)
23. Cohen JA, Antel JP,. Does interferon beta help in secondary progressive MS? Neurology. 2004; 63: 1768-1769. (Pubitemid 39532365)
24. Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW,. MSQ: Migraine-Specific Quality-of-Life Questionnaire. Further investigation of the factor structure. PharmacoEconomics. 1998; 13: 707-717. (Pubitemid 28247662)
25. Blumenfeld A, Varon S, Wilcox TK, et al,. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011; 31: 301-315.
26. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd Edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
27. Cole JC, Lin P, Rupnow MF,. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res. 2007; 16: 1231-1237. (Pubitemid 47357720)
28. Dodick DW, Turkel CC, DeGryse RE, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50: 921-936.
29. Dahlof C, Bouchard J, Cortelli P, et al,. A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life. PharmacoEconomics. 1997; 11: 24-34. (Pubitemid 27286105)
30. Martin BC, Pathak DS, Kwong J, Batenhorst AS, Sharfman M,. Assessment of the responsiveness of the Migraine-Specific Quality of Life Questionnaire (version 2.1). In:, Olesen J, Steiner TJ, Lipton RB, eds. Reducing the Burden of Headache. New York: Oxford University Press; 2003: 116-120.
31. Cole JC, Lin P, Rupnow MF,. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version. Cephalalgia. 2009; 29: 1180-1187.
32. Kosinski M, Bayliss MS, Bjorner JB, et al,. A six-item short-form survey for measuring headache impact: The HIT-6. Qual Life Res. 2003; 12: 963-974. (Pubitemid 37386625)
33. Bayliss M, Batenhorst A,. The HIT-6â.,¢: A User's Guide. Lincoln, RI: QualityMetric Incorporated; 2002.
34. Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K,. Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache. 2005; 45: 638-643. (Pubitemid 40798684)
35. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF,. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol. 2006; 59: 374-380.
36. Stewart WF, Lipton RB, Dowson AJ, Sawyer J,. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56: 20-28.
37. Spitzer RL, Kroenke K, Williams JB, Lowe B,. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med. 2006; 166: 1092-1097. (Pubitemid 43765180)
38. Kroenke K, Spitzer RL, Williams JB,. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001; 16: 606-613. (Pubitemid 32823891)
39. Kroenke K, Spitzer RL, Williams JB,. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002; 64: 258-266. (Pubitemid 34260463)
40. Kroenke K, Spitzer RL, Williams JB, Lowe B,. An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics. 2009; 50: 613-621.
41. Kroenke K, Spitzer RL, Williams JB,. The Patient Health Questionnaire-2: Validity of a two-item depression screener. Med Care. 2003; 41: 1284-1292.
42. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B,. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007; 146: 317-325. (Pubitemid 351650592)
43. Lowe B, Wahl I, Rose M, et al,. A 4-item measure of depression and anxiety: Validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord. 2010; 122: 86-95.
44. Nunnally JC, Bernstein IH,. Psychometric Theory. New York: McGraw-Hill; 1994.
45. Kerlinger F,. Foundations of Behavioral Research. New York: Holt, Rinehart & Winston; 1973.
46. Magnusson JE, Becker WJ,. Migraine frequency and intensity: Relationship with disability and psychological factors. Headache. 2003; 43: 1049-1059. (Pubitemid 37543072)
47. Jacobson GP, Ramadan NM, Aggarwal SK, Newman CW,. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology. 1994; 44: 837-842. (Pubitemid 24158796)
48. Diener HC, Dodick DW, Aurora SK, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-814.
49. Aurora SK, Dodick DW, Turkel CC, et al,. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793-803.
50. Guyatt GH, Feeny DH, Patrick DL,. Measuring health-related quality of life. Ann Intern Med. 1993; 118: 622-629. (Pubitemid 23102698)
51. Brandes JL,. The migraine cycle: Patient burden of migraine during and between migraine attacks. Headache. 2008; 48: 430-441. (Pubitemid 351517765)